Compare LOB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | MESO |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2014 | 2005 |
| Metric | LOB | MESO |
|---|---|---|
| Price | $39.48 | $16.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $43.00 | N/A |
| AVG Volume (30 Days) | 168.1K | ★ 180.2K |
| Earning Date | 04-22-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 31.95 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.52 | $629.74 |
| Revenue Next Year | $16.03 | $30.65 |
| P/E Ratio | $29.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.36 | $13.05 |
| 52 Week High | $44.53 | $21.50 |
| Indicator | LOB | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 48.95 |
| Support Level | $35.70 | $15.37 |
| Resistance Level | $42.56 | $17.10 |
| Average True Range (ATR) | 0.95 | 0.44 |
| MACD | -0.14 | -0.09 |
| Stochastic Oscillator | 19.60 | 1.06 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.